HomeNewsOpinionCOVID-19 | The virtual reality of shareholder meetings

COVID-19 | The virtual reality of shareholder meetings

With social distancing and lockdowns becoming the norm, shareholder meetings will have to take on a virtual form. Although companies, investors, and regulators may not all be prepared, this will be the new normal.

May 11, 2020 / 14:35 IST
Story continues below Advertisement
Representational picture
Representational picture

Mavia Creado and Hetal Dalal

The outbreak of COVID-19, which was declared a pandemic on March 11 by the World Health Organization (WHO), has sent shock waves across global markets and has forced unprecedented measures on the movement of people within and across the country. The Government of India’s directives of a 21-day lockdown and social distancing to avoid large public gatherings are likely to have an impact on the format of shareholder meetings (AGMs, EGMs, and NCLT convened meetings).

Story continues below Advertisement

Retail shareholders are likely to be the most affected. Institutional investors have numerous platforms to engage with company managements, but for small and retail investors, shareholder meetings are the only opportunity for shareholder engagement.

The inability to hold shareholder meetings will likely lead to a delay in transacting urgent business and to the adjournment or postponing of AGMs.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show